News|Articles|February 3, 2026
From Decline to Growth: How One Brand Expanded Access in Late Lifecycle
Author(s)CoverMyMeds
This case study leverages IQVIA data and analytics to explore how one pharmaceutical brand navigated mature lifecycle stages in a competitive class, implementing seamless prior auth strategies with CoverMyMeds where a 22 percentage point claim approval rate lift was observed, on average, helping mitigate decreasing access.
Related Content
Trending on PharmExec
1
Pharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeutics
2
Nuvation Bio’s Approach to Building a Compelling Narrative
3
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
4
Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform
5